BioSight
Companies
Solid Biosciences Inc. logo

SLDB

NASDAQCHARLESTOWN, MA
Solid Biosciences Inc.

Solid Biosciences develops gene therapy treatments for neuromuscular diseases (such as SGT-003 and SGT-212) and cardiac conditions (such as SGT-401, SGT-501, and SGT-601). The company is in the preclinical and clinical trial stages for these candidates and is working toward obtaining regulatory approval and establishing manufacturing capabilities for potential commercialization.

Price history not yet available for SLDB.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar